Microbiological rationale for alternative strategies to combat infections caused by antibiotic-resistant Pseudomonas aeruginosa

Authors

DOI:

https://doi.org/10.63341/bmbr/2.2025.31

Keywords:

surface-active antiseptics, bacteriophages, antibiotics, Pyofag, opportunistic microorganisms

Abstract

This study aimed to investigate the activity of the drug Pyofag against clinical isolates of Pseudomonas aeruginosa and to evaluate the effectiveness of the combined action of surface-active antiseptics and bacteriophages. To achieve this aim, classical methods for the isolation and identification of bacteria were employed. Antibiotic susceptibility of Pseudomonas isolates was determined using the disc diffusion method, while susceptibility to surface-active antiseptics (decamethoxine, benzalkonium chloride, chlorhexidine bigluconate, octenidine dihydrochloride, and polyhexanide) was assessed using the broth dilution method. The susceptibility of clinical isolates to Pyofag was evaluated based on the optical density of bacterial suspensions after 18 hours of incubation with the preparation. The nature of the combined effect of bacteriophages and antiseptics on P. aeruginosa was assessed by calculating the lytic index of the phage on planktonic bacterial forms cultured in media containing sub-bacteriostatic concentrations of antiseptics. The results showed that all 54 isolated clinical strains of P. aeruginosa retained high susceptibility only to reserve antibiotics – colistin (94.4%) and cefiderocol (75.9%). Resistance to other antipseudomonal antibiotics (cefepime, ceftazidime, piperacillintazobactam, imipenem, and ciprofloxacin) was observed in 96.3%-100% of isolates. However, aminoglycosides (gentamicin, tobramycin, amikacin) and meropenem remained effective against 29.6%-44.4% of strains. Antiseptic agents containing surface-active compounds demonstrated strong antipseudomonal properties and are capable of inhibiting bacterial proliferation at concentrations ranging from 16.4-22.5 μg/mL (octenidine dihydrochloride, decamethoxine, chlorhexidine bigluconate) to 65-145.7 μg/mL (polyhexanide, benzalkonium chloride). It was confirmed that decamethoxine, octenidine, and chlorhexidine exhibit significantly greater antibacterial activity than polyhexanide and benzalkonium chloride (p<0.01). The isolated Pseudomonas strains showed high susceptibility to the pharmaceutical preparation Pyofag: the lytic activity index (Is) of Pyofag exceeded 0.5 in 70.4% of strains, indicating that 50% of the bacterial population was destroyed during the dynamic interaction between bacterial growth and phage replication. In media containing sub-bacteriostatic concentrations of decamethoxine, chlorhexidine, or octenidine, both susceptible (n = 7, Is = 0.69) and resistant (n = 8, Is = 0.15) strains were lysed more intensively by the bacteriophage. This was evidenced by an increase in the susceptibility index to 0.80-0.87 in susceptible strains and to 0.54-0.70 in phage-resistant strains, respectively

Received: 06.01.2025 | Revised: 17.04.2025| Accepted: 27.05.2025

Author Biographies

Vira Bebyk, National Pirogov Memorial Medical University

Postgraduate Student 21018, 56 Pyrohov Str., Vinnytsia, Ukraine

Iryna Vovk, National Pirogov Memorial Medical University

PhD in Medical Sciences, Associate Professor 21018, 56 Pyrohov Str., Vinnytsia, Ukraine

Halyna Nazarchuk, National Pirogov Memorial Medical University

PhD in Medical Sciences, Associate Professor 21018, 56 Pyrohov Str., Vinnytsia, Ukraine

Nataliia Bahniuk, National Pirogov Memorial Medical University

PhD in Medical Sciences, Assistant 21018, 56 Pyrohov Str., Vinnytsia, Ukraine

Oleksandr Nazarchuk, National Pirogov Memorial Medical University

Doctor of Medical Science, Professor 21018, 56 Pyrohov Str., Vinnytsia, Ukraine

References

Green SI, Clark JR, Santos HH, Weesner KE, Salazar KC, Aslam S, et al. A retrospective, observational study of 12 cases of expanded-access customized phage therapy: Production, characteristics, and clinical outcomes. Clin Infect Dis. 2023;77(8):1079–91. DOI: 10.1093/cid/ciad335

Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: A multicentre, multinational, retrospective observational study. Nat Microbiol. 2024;9:1434–53. DOI: 10.1038/s41564-024-01705-x

Cesta N, Pini M, Mulas T, Materazzi A, Ippolito E, Wagemans J, et al. Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: An Italian real-life experience and in vitro analysis. Open Forum Infect Dis. 2023;10(2):ofad51. DOI: 10.1093/ofid/ofad051

Young MJ, Hall LML, Merabishvilli M, Pirnay JP, Clark JR, Jones JD. Phage therapy for diabetic foot infection: A case series. Clin Ther. 2023;45(8):797–801. DOI: 10.1016/j.clinthera.2023.06.009

Rahimzadeh Torabi L, Doudi M, Naghavi NS, Monajemi R. Isolation, characterization, and effectiveness of bacteriophage Pɸ-Bw-Ab against XDR Acinetobacter baumannii isolated from nosocomial burn wound infection. Iran J Basic Med Sci. 2021;24(9):1254–63. DOI: 10.22038/ijbms.2021.57772.12850

Racenis K, Lacis J, Rezevska D, Mukane L, Vilde A, Putnins I, et al. Successful bacteriophage-antibiotic combination therapy against multidrug-resistant Pseudomonas aeruginosa left ventricular assist device driveline infection. Viruses. 2023;15(5):1210. DOI: 10.3390/v15051210

Rubezhniak I. Antibacterial activities of cultural filtrates of some strains of micromycete. Biol Syst Theory Innov. 2020;11(2):42–9. DOI: 10.31548/biologiya2020.01.042

Order of the Cabinet of Ministers of Ukraine No. 116-p. National Action Plan to Combat Antimicrobial Resistance [Internet]. 2019 March 6 [cited 2024 December 20]. Available from: https://www.fao.org/faolex/results/details/en/c/LEX-FAOC187629/

EUCAST recommendations version 13 [Internet]. 2023 January 2 [cited 2024 December 20]. Available from: https://www.eucast.org/eucast_news/news_singleview?tx_ttnews%5Btt_news%5D=518&cHash=2509b0db92646dffba041406dcc9f20c

Band M. An introduction to medical statistics. 4th ed. Oxford: University Press; 2015. 447 P.

Kovalchuk V, Kondratiuk V, McGann P, Jones BT, Fomina N, et al. Temporal evolution of bacterial species and their antimicrobial resistance characteristics in wound infections of war-related injuries in Ukraine from 2014 to 2023. J Hosp Infect. 2024;152:99–104. DOI: 10.1016/j.jhin.2024.06.011

Khan ID, Malik M, Rajmohan KS, Banerjee P, Khan S, Panda PS, et al. Hemophagocytosis secondary to pharyngeal abscess in an immunocompetent patient (case report). Int J Med Med Res. 2018;4(1):41–4. DOI: 10.11603/ijmmr.2413-6077.2018.1.8514

Bahniuk N, Faustova M, Riesbeck K, Prokopchuk Z, Paliy V, Nazarchuk O, et al. The correspondence of the carbapenemase genotype and phenotypic antimicrobial profiles of Pseudomonas aeruginosa. Med Ecol Probl. 2023;27(5–6):45–50. DOI: 10.31718/mep.2023.27.5-6.06

Mudenda S, Daka V, Matafwali SK. World Health Organization AWaRe framework for antibiotic stewardship: Where are we now and where do we need to go? An expert viewpoint. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e84. DOI: 10.1017/ash.2023.164

Nazarchuk O, Nagaichuk V, Bahniuk N, Nazarchuk H, Rymsha O, Dobrovanov O, et al. Susceptibility to antimicrobials of Acinetobacter baumannii and Pseudomonas aeruginosa clinical strains and their blaVIM variants in ICU of regional burn centre. Lek Obz. 2023;72(1):18–23.

World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report [Internet]. 2021 [cited 2024 December 20]. Available from: https://iris.who.int/bitstream/handle/10665/341666/9789240027336-eng.pdf?sequence=1

Denysko Т. Comparative study of antimicrobial properties of biomaterials and dressings based on antiseptics against gram-negative bacteria as pathogens of wound infections. Bull Probl Biol Med. 2024;1(172):357–63. DOI: 10.29254/2077-4214-2024-1-172-357-363

Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, et al. Progress in alternative strategies to combat antimicrobial resistance: Focus on antibiotics. Antibiotics. 2022;11(2):200. DOI: 10.3390/antibiotics11020200

Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2018;19(1):35–45. DOI: 10.1016/S1473-3099(18)30482-1

Nawaz A, Khalid NA, Zafar S, Majid A, Shahzadi M, Saleem S, et al. Phage therapy as a revolutionary treatment for multidrug-resistant Pseudomonas aeruginosa infections: A narrative review. Microbe. 2024;2:100030. DOI: 10.1016/j.microb.2023.100030

Torres-Barceló C, Hochberg ME. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 2016;24(4):249–56. DOI: 10.1016/j.tim.2015.12.011

Derkach S. Bacteriophages: Current issues of phase preparation and evaluation of their activity. Infect Dis. 2022;1:5–10. DOI: 10.11603/1681-2727.2022.1.13014

Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, et al. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas Aeruginosa infection in endocarditis and reduces virulence. J Infect Dis. 2017;215(5):703–12. DOI: 10.1093/infdis/jiw632

Cui L, Watanabe S, Miyanaga K, Kiga K, Sasahara T, Aiba Y, et al. A comprehensive review on phage therapy and phage-based drug development. Antibiotics. 2024;13(9):870. DOI: 10.3390/antibiotics13090870

Downloads

Published

2025-06-05

How to Cite

Bebyk, V., Vovk, I., Nazarchuk, H., Bahniuk, N., & Nazarchuk, O. (2025). Microbiological rationale for alternative strategies to combat infections caused by antibiotic-resistant Pseudomonas aeruginosa. Bulletin of Medical and Biological Research, (2), 31–39. https://doi.org/10.63341/bmbr/2.2025.31